This HTML5 document contains 111 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/pubchem-compound/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/pubchem-substance/
n19http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/national-drug-code-directory/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/chemspider/
n15http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00653/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00653
rdf:type
n3:Drug
n3:description
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
n3:dosage
n4:271B6262-363D-11E5-9242-09173F13E4C5 n4:271B6263-363D-11E5-9242-09173F13E4C5 n4:271B6264-363D-11E5-9242-09173F13E4C5 n4:271B6265-363D-11E5-9242-09173F13E4C5 n4:271B625F-363D-11E5-9242-09173F13E4C5 n4:271B6266-363D-11E5-9242-09173F13E4C5 n4:271B6267-363D-11E5-9242-09173F13E4C5 n4:271B6268-363D-11E5-9242-09173F13E4C5 n4:271B6269-363D-11E5-9242-09173F13E4C5 n4:271B626A-363D-11E5-9242-09173F13E4C5 n4:271B626B-363D-11E5-9242-09173F13E4C5 n4:271B626C-363D-11E5-9242-09173F13E4C5 n4:271B626D-363D-11E5-9242-09173F13E4C5 n4:271B626E-363D-11E5-9242-09173F13E4C5 n4:271B6260-363D-11E5-9242-09173F13E4C5 n4:271B6261-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, Rowe BH: Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005 Jul;128(1):337-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16002955 # Yokoyama K, Takahashi N, Yada Y. Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010;86(3):187-91. Epub 2010 Mar 12. # Wedig KE, Kogan J, Schorry EK et al. Skeletal demineralization and fractures caused by fetal magnesium toxicity. J Perinatol. 2006; 26(6):371-4. # Nassar AH, Sakhel K, Maarouf H, et al. Adverse maternal and neonatal outcome of prolonged course of Magnesium Sulfate tocolysis. Acta Obstet Gynecol Scan. 2006;85(9):1099-103. # Malaeb SN, Rassi A, Haddad MC. Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labor. Pediatr Radiol. 2004;34(5):384-6. Epub 2004 Feb 18. # Matsuda Y, Maeda Y, Ito M, et al. Effect of Magnesium Sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8. # Schanler RJ, Smith LG, Burns PA. Effects of long-term maternal intravenous Magnesium Sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41. # Santi MD, Henry GW, Douglas GL. Magnesium Sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop. 1994;14(2):249-53. # Holcomb WL, Shackelford GD, Petrie RH. Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991; 78(4):611-4. # Cumming WA, Thomas VJ. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. Am J Roentgenol. 1989; 152(5):1071-2. # Lamm CL, Norton KL, Murphy RJ. Congenital rickets associated with Magnesium Sulfate infusion for tocolysis. J Pediatr. 1988; 113(6):1078-82. # McGuinness GA, Weinstein MM, Cruikshank DP, et al. Effects of Magnesium Sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980;56(5): 595-600. # Riaz M, Porat R, Brodsky NL, et al. The effects of maternal Magnesium Sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998;18(6 pt 1):449-54.
n3:group
approved
n3:halfLife
43.2 hours (for newborns)
n3:indication
Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.
n3:manufacturer
n5:271B624F-363D-11E5-9242-09173F13E4C5 n5:271B6250-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00653 n29:DB00653
dcterms:title
Magnesium Sulfate
adms:identifier
n12:D01108 n13:0409-6729-23 n14:DB00653 n16:32599 n17:23226 n23:46508411 n24:PA450302 n25:Magnesium_Sulfate n26:24083
n3:mechanismOfAction
Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca<sup>2+</sup> influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.
n3:packager
n5:271B624B-363D-11E5-9242-09173F13E4C5 n5:271B624C-363D-11E5-9242-09173F13E4C5 n5:271B6249-363D-11E5-9242-09173F13E4C5 n5:271B624A-363D-11E5-9242-09173F13E4C5 n5:271B624D-363D-11E5-9242-09173F13E4C5 n5:271B624E-363D-11E5-9242-09173F13E4C5 n5:271B6247-363D-11E5-9242-09173F13E4C5 n5:271B6248-363D-11E5-9242-09173F13E4C5 n5:271B6246-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Magnesium is excreted solely by the kidney at a rate proportional to the serum concentration and glomerular filtration.
n3:synonym
Magnesium sulfate (1:1) Magnesium sulfate anhydrous Magnesium(ii) sulfate MgSO4 Magnesiumsulfat Magnesium sulphate
n3:toxicity
LD<sub>50</sub> = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.
n6:hasAHFSCode
n7:92-02-00%2A n7:84-92-00 n7:28-12-92 n7:56-12-00 n7:40-12-00
n3:proteinBinding
25-30%
n3:synthesisReference
Shinichi Yamamoto, Akifumi Sekitani, "BASIC MAGNESIUM SULFATE GRANULE, AND PROCESS FOR PRODUCTION THEREOF." U.S. Patent US20110042297, issued February 24, 2011.
n27:hasConcept
n28:M0012889
foaf:page
n9:mgso4.htm n20:magnesium-sulfate.html
n3:IUPAC-Name
n15:271B6270-363D-11E5-9242-09173F13E4C5
n3:InChI
n15:271B6276-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n15:271B6275-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n15:271B6272-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n15:271B6273-363D-11E5-9242-09173F13E4C5
n3:SMILES
n15:271B6274-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n15:271B6285-363D-11E5-9242-09173F13E4C5
n3:logP
n15:271B626F-363D-11E5-9242-09173F13E4C5 n15:271B6287-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n10:D11AX05 n10:B05XA05 n10:A06AD04 n10:V04CC02 n10:A12CC02
n3:H-Bond-Acceptor-Count
n15:271B627C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n15:271B627D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n15:271B6277-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n15:271B6278-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n15:271B627A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n15:271B6279-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n15:271B627B-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7487-88-9
n3:category
n3:containedIn
n21:271B6251-363D-11E5-9242-09173F13E4C5 n21:271B6252-363D-11E5-9242-09173F13E4C5 n21:271B625B-363D-11E5-9242-09173F13E4C5 n21:271B6255-363D-11E5-9242-09173F13E4C5 n21:271B6256-363D-11E5-9242-09173F13E4C5 n21:271B6253-363D-11E5-9242-09173F13E4C5 n21:271B6254-363D-11E5-9242-09173F13E4C5 n21:271B6259-363D-11E5-9242-09173F13E4C5 n21:271B625A-363D-11E5-9242-09173F13E4C5 n21:271B6257-363D-11E5-9242-09173F13E4C5 n21:271B6258-363D-11E5-9242-09173F13E4C5 n21:271B625D-363D-11E5-9242-09173F13E4C5 n21:271B625E-363D-11E5-9242-09173F13E4C5 n21:271B625C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n15:271B6281-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n15:271B6283-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n15:271B6284-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n15:271B6286-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n15:271B6280-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n15:271B627F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n15:271B6282-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n15:271B6271-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n15:271B627E-363D-11E5-9242-09173F13E4C5